Nifty Pharma index set to post biggest weekly rally in 15 years
At 11:23 am; Nifty Pharma index, the largest gainer among sectoral indices, was up 2.2% at 9,310, surging 8.2% thus far in current week.
 "Nifty Pharma index set to post biggest weekly rally in 15 years")
premium
Shares of pharmaceutical companies are on a roll with the Nifty Pharma index all set to post its biggest weekly gain in 15 years following the positive news flow from the corporate levels with regard to regulatory issues.
At 11:23 am; the Nifty Pharma index -- largest gainer among sectoral indices, was up 2.2% at 9,310, surging 8.2% thus far in current week. Earlier, in week ended August 31, 2003, the index had recorded 9.1% gain.
Nifty Pharma index was quoting higher for the eight straight trading days on the National Stock Exchange (NSE). During the period, the pharma index rallied 15% as compared to 2% rise in the benchmark Nifty 50 index.
Dr Reddy’s Laboratories, Lupin, Cadila Healthcare, Sun Pharmaceutical Industries, Aurobindo Pharma and Cipla from the Nifty Pharma index were up in the range of 8% to 14% thus far in the current week. Alembic Pharmaceuticals, Granules India, Marksans Pharma, Ajanta Pharma and Suven Lifesciences, the non-index pharma gained between 9% and 20% during the week.
Dr Reddy’s Labs was up 4% to Rs 2,365 today, after the U.S. Food and Drug Administration (USFDA) approved the first generic versions of Indivior’s Suboxone sublingual film for the treatment of opioid dependence. The stock rallied 14% so far in current week.
Lupin gained 3% at Rs 923, too rallied 14% in past five trading sessions. The company on Thursday it has received approval from the US health regulator to market Drospirenone, Ethinyl Estradiol, Levomefolate Calcium tablets, used to prevent pregnancy, in the American market.
While, during the week, Sun Pharma announced the resolution of regulatory compliance issues at Halol plant, Aurobindo Pharma gained on the back of US FDA (Food and Drug Administration) approval for Omeprazole (used to treat certain stomach and esophagus problems). Both these stocks have gained 8% so far in current week.
At 11:23 am; the Nifty Pharma index -- largest gainer among sectoral indices, was up 2.2% at 9,310, surging 8.2% thus far in current week. Earlier, in week ended August 31, 2003, the index had recorded 9.1% gain.
Nifty Pharma index was quoting higher for the eight straight trading days on the National Stock Exchange (NSE). During the period, the pharma index rallied 15% as compared to 2% rise in the benchmark Nifty 50 index.
Dr Reddy’s Laboratories, Lupin, Cadila Healthcare, Sun Pharmaceutical Industries, Aurobindo Pharma and Cipla from the Nifty Pharma index were up in the range of 8% to 14% thus far in the current week. Alembic Pharmaceuticals, Granules India, Marksans Pharma, Ajanta Pharma and Suven Lifesciences, the non-index pharma gained between 9% and 20% during the week.
Dr Reddy’s Labs was up 4% to Rs 2,365 today, after the U.S. Food and Drug Administration (USFDA) approved the first generic versions of Indivior’s Suboxone sublingual film for the treatment of opioid dependence. The stock rallied 14% so far in current week.
Lupin gained 3% at Rs 923, too rallied 14% in past five trading sessions. The company on Thursday it has received approval from the US health regulator to market Drospirenone, Ethinyl Estradiol, Levomefolate Calcium tablets, used to prevent pregnancy, in the American market.
While, during the week, Sun Pharma announced the resolution of regulatory compliance issues at Halol plant, Aurobindo Pharma gained on the back of US FDA (Food and Drug Administration) approval for Omeprazole (used to treat certain stomach and esophagus problems). Both these stocks have gained 8% so far in current week.
| COMPANY | LATEST | 1-WEEK BEFORE | GAIN(%) |
| ALEMBIC PHARMA | 523.55 | 435.25 | 20.29 |
| DR REDDY'S LABS | 2358.25 | 2062.90 | 14.32 |
| LUPIN | 920.50 | 810.05 | 13.63 |
| GRANULES INDIA | 89.10 | 78.80 | 13.07 |
| MARKSANS PHARMA | 31.50 | 27.95 | 12.70 |
| AJANTA PHARMA | 1082.80 | 976.35 | 10.90 |
| CADILA HEALTH. | 400.75 | 364.35 | 9.99 |
| SUVEN LIFE SCIE. | 235.20 | 214.70 | 9.55 |
| AUROBINDO PHARMA | 620.25 | 572.35 | 8.37 |
| SUN PHARMA.INDS. | 572.00 | 528.25 | 8.28 |
| CIPLA | 604.75 | 559.65 | 8.06 |
| BLISS GVS PHARMA | 187.50 | 173.65 | 7.98 |
| WOCKHARDT | 743.00 | 689.30 | 7.79 |
| GLENMARK PHARMA. | 597.50 | 556.75 | 7.32 |
| DISHMAN CARBOGEN | 317.00 | 295.50 | 7.28 |
| STRIDES SHASUN | 380.50 | 357.55 | 6.42 |
| GLAXOSMI. PHARMA | 2787.05 | 2629.90 | 5.98 |
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%